Irritable Bowel Syndrome Treatment Market is estimated to reach USD 7.5 Billion by 2034, with a CAGR of 8.8%

Irritable bowel syndrome treatment market is driven by increasing incidences of gastrointestinal disorder disease owing to rising levels of stress and adoption of sedentary lifestyle. Irritable Bowel Syndrome Market Size was valued at USD 3.5 Billion in 2024 and is expected to reach USD 7.5 Billion by 2034, growing at a CAGR of 8.8%.

The report “Irritable Bowel Syndrome Market Size, Share, By Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and Others), By Medical Condition (IBS Diarrhea and IBS Constipation), By Distribution Channels (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and By Region - Trends, Analysis and Forecast till 2034"

Key Highlights:

• Sucampo Pharmaceutical, Inc. collaborated with Herbin Gloria Pharmaceuticals to commercialize AMITIZA (lubiprostone) in China in 2015.
• In 2019, British pharmaceutical giant AstraZeneca has obtained approval from the National Medical Products Administration to market its drug linaclotide in China.

Key Market Insights from the report:          

Irritable bowel syndrome market size was valued at USD 3.5 Billion in 2024 and is expected to reach USD 7.5 Billion by 2034, growing at a CAGR of 8.8%. The market report has been segmented on the basis of drug type, medical condition, distribution channel, and region.

• By drug type, the irritable bowel syndrome treatment market has been segmented into Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and others.
• By medical condition, irritable bowel syndrome treatment market is segmented into IBS diarrhea and IBS constipation.
• By distribution channel, irritable bowel syndrome treatment market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.
• By region, the North America accounts for major share in terms of revenue in the irritable bowel syndrome treatment market owing to high degree of therapeutic needs and penetration of generic drugs in this region.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Irritable Bowel Syndrome Market Size, Share, By Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and Others), By Medical Condition (IBS Diarrhea and IBS Constipation), By Distribution Channels (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and By Region - Trends, Analysis and Forecast till 2034"

 

The key players operating in the Irritable Bowel Syndrome Market include Ironwood Pharmaceuticals, Allergan plc, Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd., Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, AstraZeneca plc, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., and Ardelyx Inc.

About Prophecy Market Insights

Prophecy Market Insights is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- [email protected]

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com